8 citations
,
July 2022 in “International Journal of Molecular Sciences” 17β-estradiol lowers polyamine oxidase levels in breast cancer cells through estrogen receptor 2.
September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
July 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” The study developed a 3D model that closely imitates remaining ovarian cancer after treatment and identified a potential drug targeting resistant cancer cells.
January 2026 in “ACS Applied Bio Materials” A new treatment using nanoliposomes can improve hair regrowth in androgenetic alopecia.
May 2025 in “Journal of the ASEAN Federation of Endocrine Societies” Thorough evaluation is crucial for postmenopausal women with virilization to detect rare ovarian tumors.
18 citations
,
October 2010 in “Bioorganic & Medicinal Chemistry Letters” New hybrid compound found to effectively prevent hair loss.
August 2013 in “Nature Reviews Drug Discovery” New treatments for cancer and skin disorders show promise in disrupting harmful cell interactions and promoting hair growth.
3 citations
,
November 1998 in “PubMed” January 2011 in “Yearbook of Endocrinology”
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
3 citations
,
July 2025 in “Obesity Facts” GLP-1 receptor analogs may help improve metabolism and reproductive health in people with PCOS and obesity.
6 citations
,
April 2004 in “Journal of Enzyme Inhibition and Medicinal Chemistry” New progesterone-based compounds can block male hormones.
19 citations
,
September 2019 in “British Journal of Dermatology” FOL-005 peptide can reduce human hair growth by lowering FGF7 levels.
April 2022 in “DOAJ (DOAJ: Directory of Open Access Journals)” Polygonum multiflorum may treat hair loss by reducing inflammation and stress, and boosting melanin.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
March 2024 in “Clinical, cosmetic and investigational dermatology” Upadacitinib may effectively treat alopecia areata without side effects.
1 citations
,
April 2020 in “Journal of the Endocrine Society” Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.
April 2023 in “Cancer Research” Plucked hair can effectively monitor drug effects in cancer treatment.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly” June 2015 in “Reactions weekly” December 2012 in “Reactions weekly”
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
1 citations
,
October 2023 in “Clinical, cosmetic and investigational dermatology” Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib is a safe and effective treatment for severe alopecia areata.
34 citations
,
April 1982 in “BMJ” January 2026 in “Journal of the American Academy of Dermatology” 5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than metformin for reducing type 2 diabetes risk.